Literature DB >> 28835580

Epoxyeicosatrienoic Acids are Mediated by EPHX2 Variants and may be a Predictor of Early Neurological Deterioration in Acute Minor Ischemic Stroke.

Xingyang Yi1, Jing Lin2, Jie Li1, Qiang Zhou2, Zhao Han3.   

Abstract

AIM: To investigatethe association of plasma epoxyeicosatrienoic acids (EETs) with early neurologic deterioration (END), and whether EETs are mediated by EPHX2 variants in patients with minor ischemic stroke (MIS).
METHOD: This was a prospective, multi-center observational study in patients with acute MIS in the Chinese population.Plasma EETs levels were measured on admission. Single nucleotide polymorphisms (SNPs) of EPHX2 rs751141 were genotyped using mass spectrometry. The primary outcome was END within 10 days after admission. END was defined as an increase in NIHSS of 2 or more points. The degree of disability was assessed using the modified Rankin Scale (mRS) at 3 months after admission.
RESULTS: A total of 322 patients were enrolled, of which 85 patients (26.4%) experienced END. The mean EETs level was 64.1±7.5 nmol/L. EETs levels were significantly lower in patients with END compared to patients without END. Frequency of EPHX2 rs751141 GG was higher in patients with END than in patients without END, and EPHX2 rs751141 GG genotype was associated with lower EETs levels. Low level (<64.4 nmol/L) of EETs was an independent predictor of END (first and second quartiles) in multivariate analyses. END was associated with a higher risk of poor outcome (mRS scores 3-6) at 3 months.
CONCLUSION: END is fairly common and associated with poor outcomes in acute MIS. EPHX2 variants may mediate EETs levels, and low levels of EETs may be a predictor for END in acute MIS.

Entities:  

Keywords:  EPHX2 variants; Early neurological deterioration; Epoxyeicosatrienoic acids; Minor ischemic stroke; Outcome

Mesh:

Substances:

Year:  2017        PMID: 28835580      PMCID: PMC5742371          DOI: 10.5551/jat.41145

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  31 in total

Review 1.  Cytochrome P450 eicosanoids and cerebral vascular function.

Authors:  John D Imig; Alexis N Simpkins; Marija Renic; David R Harder
Journal:  Expert Rev Mol Med       Date:  2011-03-01       Impact factor: 5.600

2.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Authors:  Yongjun Wang; Yilong Wang; Xingquan Zhao; Liping Liu; David Wang; Chunxue Wang; Chen Wang; Hao Li; Xia Meng; Liying Cui; Jianping Jia; Qiang Dong; Anding Xu; Jinsheng Zeng; Yansheng Li; Zhimin Wang; Haiqin Xia; S Claiborne Johnston
Journal:  N Engl J Med       Date:  2013-06-26       Impact factor: 91.245

3.  Genetic markers in the EET metabolic pathway are associated with outcomes in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Mark K Donnelly; Yvette P Conley; Elizabeth A Crago; Dianxu Ren; Paula R Sherwood; Jeffery R Balzer; Samuel M Poloyac
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-12       Impact factor: 6.200

4.  Deteriorating ischemic stroke in 4 clinical categories classified by the Oxfordshire Community Stroke Project.

Authors:  H Tei; S Uchiyama; K Ohara; M Kobayashi; Y Uchiyama; M Fukuzawa
Journal:  Stroke       Date:  2000-09       Impact factor: 7.914

5.  CYP Genetic Variants, CYP Metabolite Levels, and Symptomatic Carotid Stenosis in Ischemic Stroke Patients.

Authors:  Xingyang Yi; Duanxiu Liao; Lang Wu; Hong Chen; Jie Li; Chun Wang
Journal:  J Atheroscler Thromb       Date:  2015-12-19       Impact factor: 4.928

6.  20-Hydroxyeicosatetraenoic Acid as a Predictor of Neurological Deterioration in Acute Minor Ischemic Stroke.

Authors:  Xingyang Yi; Zhao Han; Qiang Zhou; Jing Lin; Ping Liu
Journal:  Stroke       Date:  2016-11-10       Impact factor: 7.914

7.  Factors associated with early outcome in patients with large-vessel carotid strokes.

Authors:  Elisa Cuadrado-Godia; Sara Jimena; Angel Ois; Ana Rodríguez-Campello; Eva Giralt-Steinhauer; Carol Soriano-Tarraga; Jordi Jiménez-Conde; José Enrique Martínez-Rodríguez; Jaume Capellades; Jaume Roquer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-10-02       Impact factor: 10.154

8.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01

9.  Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred.

Authors:  Keiko Sato; Mitsuru Emi; Yoichi Ezura; Yuko Fujita; Daisuke Takada; Tomoaki Ishigami; Satoshi Umemura; Yunpei Xin; Lily L Wu; Stacey Larrinaga-Shum; Susan H Stephenson; Steven C Hunt; Paul N Hopkins
Journal:  J Hum Genet       Date:  2003-12-13       Impact factor: 3.172

10.  Soluble epoxide hydrolase gene deletion improves blood flow and reduces infarct size after cerebral ischemia in reproductively senescent female mice.

Authors:  Kristen L Zuloaga; Wenri Zhang; Natalie E Roese; Nabil J Alkayed
Journal:  Front Pharmacol       Date:  2015-01-15       Impact factor: 5.810

View more
  6 in total

Review 1.  Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation.

Authors:  Sean D Kodani; Christophe Morisseau
Journal:  Biochimie       Date:  2019-02-01       Impact factor: 4.079

2.  The Human Genetic Variants CYP2J2 rs2280275 and EPHX2 rs751141 and Risk of Diabetic Nephropathy in Egyptian Type 2 Diabetic Patients.

Authors:  Mona S Habieb; Ashraf A Dawood; Mahmoud M Emara; Mohammad G Elhelbawy; Nesreen G Elhelbawy
Journal:  Appl Clin Genet       Date:  2020-11-19

Review 3.  Soluble Epoxide Hydrolase and Diabetes Complications.

Authors:  Natasha Z Anita; Walter Swardfager
Journal:  Int J Mol Sci       Date:  2022-06-02       Impact factor: 6.208

4.  Association between the EPHX2 p.Lys55Arg polymorphism and prognosis following an acute coronary syndrome.

Authors:  Akinyemi Oni-Orisan; Sharon Cresci; Philip G Jones; Katherine N Theken; John A Spertus; Craig R Lee
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-08-07       Impact factor: 3.072

5.  Matrix metalloproteinase-9 gene polymorphisms are associated with ischemic stroke severity and early neurologic deterioration in patients with atrial fibrillation.

Authors:  Xingyang Yi; Qiang Zhou; Guo Sui; Daofeng Fan; Yongyin Zhang; Minjie Shao; Zhao Han; Hua Luo; Jing Lin; Ju Zhou
Journal:  Brain Behav       Date:  2019-04-22       Impact factor: 2.708

6.  A Single-Center Clinical Study to Evaluate Shenxiong Glucose Injection Combined with Edaravone in the Treatment of Acute Large-Area Cerebral Infarction.

Authors:  Zongqin Li; Xiaoxia Rong; Jun Luo; Tao Zeng; Pan Huang; Xuejie Xu
Journal:  Biomed Res Int       Date:  2021-06-29       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.